Vir retains a 50-50 profit split and co-promotion option in the U.S., while receiving tiered double-digit royalties on ex-U.S ...
Advanced Micro Devices rallies after the chip maker unveils a multi-year deal to supply computing power to Meta Platforms, ...
Joining me on today's call from Vir Biotechnology, Inc., are Dr. Marianne De Backer, our Chief Executive Officer, Dr. Mark D.
Astellas Pharma Inc. and Vir Biotechnology, Inc. have entered into a global strategic collaboration to advance VIR-5500, an ...
Siren Biotechnology, pioneers of Universal AAV Immuno-Gene Therapy for cancer, today announced that the U.S. Food and Drug ...
Experts discuss biotechnology's role in advancing personalized medicine at a VIT webinar, highlighting career opportunities ...
BENGALURU: Karnataka biotechnology sector’s economy has hit $39.2 billion (Rs 3.25 lakh crore), accounting for over 10% of ...
Vir Biotechnology Inc. VIR shares are up during Tuesday’s premarket session following a significant strategic collaboration ...
Researchers at the Department of Chemical Engineering and Biotechnology (CEB) have found a new way to organize molecules inside living cells, opening possibilities for more controlled and efficient ...
Ongoing Phase 3 full approval clinical trial of ateganosine holds high probability of technical success for interim and full analysis ...
Vir Biotechnology and Astellas entered a license agreement to co-develop and commercialize Vir's prostate cancer treatment. The agreement is for VIR-5500, a dual-masked T-cell engager targeting ...
The central question is no longer whether we can innovate, but whether innovation can truly reach patients in time.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results